Discovering and developing oncology therapeutics requires consideration of very specific clinical and molecular characteristics within targeted patient populations, and even sub-populations. Drug development programs can be advanced more efficiently with the support of sophisticated translational research tools, such as PDX models in an ex vivo and in vivo setting.

Champions Oncology PDX models are the most highly-characterized, clinically-relevant cohorts of PDX models to optimally predict success and accelerate the drug development process.

This webinar will provide an overview of the various unique and advanced translational tools that are offered by Champions oncology in an in vivo and ex vivo setting.

Featured Speaker

Maria Mancini, PhD

Vice President of Pharmacology
Champions Oncology

Maria Mancini, PhD, joined Champions in March of 2015 and serves as Vice President of Pharmacology overseeing the scientific operations of pharmacology research initiatives including pre-clinical, co-clinical and CLIA approved drug sensitivity testing. She previously served as the Director of Research for Biomodels LLC leading efforts to generate translational in vivo platforms to test the efficacy of agents developed to treat cancer and cancer regimen-related toxicities. 

NOW AVAILABLE ON-DEMAND

Register now for this webinar